Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Galmed Pharmaceuticals
(NASDAQ:GLMD)
Intraday
$0.3641
0
[0.00%]
After-Hours
$0.3641
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.3641
0
[0.00%]
At close: Apr 23
$0.3641
0
[0.00%]
After Hours: 4:41PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Galmed Pharmaceuticals Stock (NASDAQ:GLMD)
Galmed Pharmaceuticals Stock (NASDAQ: GLMD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 10, 2024
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Apr 10, 2024, 8:12AM
Monday, April 08, 2024
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Apr 8, 2024, 1:10PM
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Apr 8, 2024, 5:15AM
Tuesday, March 19, 2024
On March 19, Galmed Pharmaceuticals Got Letter From Nasdaq That Granted Co Additional 180 Calendar Day Period To Regain Compliance
Benzinga Newsdesk
-
Mar 19, 2024, 5:01PM
Friday, March 15, 2024
Galmed Announces Grant Of New Patent For Combination Of Aramchol With Resmetirom (MGL-3196, REZDIFFRA) For Treatment Of NASH And Liver Fibrosis
Benzinga Newsdesk
-
Mar 15, 2024, 9:02AM
Tuesday, November 21, 2023
Gold Rises 1%; Hibbett Shares Spike Higher
Lisa Levin
-
Nov 21, 2023, 2:34PM
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Nov 21, 2023, 1:28PM
Nasdaq Falls Over 100 Points; Burlington Shares Jump After Q3 Results
Lisa Levin
-
Nov 21, 2023, 12:04PM
Galmed Pharmaceuticals shares are trading lower after the company announced a delay of at least six months in the initiation of its Primary Sclerosing Cholangitis Ph 2a Study.
Benzinga Newsdesk
-
Nov 21, 2023, 11:45AM
US Stocks Down; Chicago Fed National Activity Index Falls In October
Lisa Levin
-
Nov 21, 2023, 9:52AM
Monday, November 20, 2023
Galmed Announces A Delay Of At Least Six Months In The initiation Of Its Primary Sclerosing Cholangitis Phase 2a Study
Benzinga Newsdesk
-
Nov 20, 2023, 4:34PM
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 3, 2023, 2:37PM
Monday, October 02, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 2, 2023, 1:00PM
Galmed Pharmaceuticals Has Been Granted European Patent Number EP3538158 Titled "Treatment For Fibrosis (Including Methods For Inhibition Of Fibrotic Disorders And Hepato-Fibrotic Conditions Associated With NAFLD And NASH)"
Benzinga Newsdesk
-
Oct 2, 2023, 10:24AM
Wednesday, September 27, 2023
Why Galecto Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Sep 27, 2023, 8:15AM
Tuesday, September 26, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Sep 26, 2023, 12:04PM
Galmed Announces Allowance Of New Patent For Aramchol For The Treatment Of Pulmonary And Dermal Fibrosis
Benzinga Newsdesk
-
Sep 26, 2023, 8:43AM
Friday, September 22, 2023
Galmed Pharmaceuticals Announces Receipt Of Nasdaq Minimum Bid Price Notification
Benzinga Newsdesk
-
Sep 22, 2023, 4:07PM
Monday, August 07, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Aug 7, 2023, 12:13PM
Thursday, August 03, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Aug 3, 2023, 2:45PM
Monday, July 24, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Benzinga Insights
-
Jul 24, 2023, 11:00AM
Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target
Benzinga Newsdesk
-
Jul 24, 2023, 8:57AM
Friday, July 21, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Jul 21, 2023, 1:24PM
Galmed Pharmaceuticals 13D Filing Shows CVI Investments, Inc. Increased Stake In Co To 9.9% As Of July 14
Happy Mohamed
-
Jul 21, 2023, 10:17AM
Tuesday, July 18, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Jul 18, 2023, 1:47PM
Monday, July 17, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Jul 17, 2023, 12:17PM
Friday, July 14, 2023
Nasdaq Drops 50 Points; Wells Fargo Earnings Beat Views
Lisa Levin
-
Jul 14, 2023, 3:06PM
Galmed Pharmaceuticals shares are trading lower after the company announced pricing of a $7 million public offering.
Benzinga Newsdesk
-
Jul 14, 2023, 1:42PM
Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Jul 14, 2023, 12:53PM
Crude Oil Down 2%; Citigroup Profit Tops Estimates
Lisa Levin
-
Jul 14, 2023, 12:13PM
Galmed Pharmaceuticals Ltd. Shares Resume Trade
Happy Mohamed
-
Jul 14, 2023, 9:37AM
Galmed Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Down -26.4%
Happy Mohamed
-
Jul 14, 2023, 9:33AM
Galmed Pharmaceuticals Announces Pricing Of $7M Public Offering Of 5.6M Shares And Warrants At A Purchase Price Of $1.25/Share
Happy Mohamed
-
Jul 14, 2023, 9:31AM
Thursday, July 13, 2023
Why Progressive Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Jul 13, 2023, 12:49PM
Why Senmiao Technology Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jul 13, 2023, 8:12AM
Wednesday, July 12, 2023
Galmed Pharmaceuticals Shares Resume Trading
Benzinga Newsdesk
-
Jul 12, 2023, 12:06PM
Monday, July 10, 2023
Galmed To Employ OnKai's Disruptive Artificial Intelligence In Its Planned Phase 2a Clinical Trial In PSC
Happy Mohamed
-
Jul 10, 2023, 8:05AM
Thursday, July 06, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Jul 6, 2023, 12:58PM
Thursday, June 01, 2023
Recap: Galmed Pharmaceuticals Q1 Earnings
Benzinga Insights
-
Jun 1, 2023, 9:40AM
Galmed Pharmaceuticals Q1 EPS $(1.09) Beats $(1.50) Estimate
Happy Mohamed
-
Jun 1, 2023, 8:12AM
Monday, May 15, 2023
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
May 15, 2023, 1:45PM
Tuesday, May 09, 2023
Galmed Announces Initiation Of A Clinical Development Program To Evaluate Aramchol meglumine For Treatment Of Primary Sclerosing Cholangitis
Benzinga Newsdesk
-
May 9, 2023, 7:17AM
Monday, May 08, 2023
Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
May 8, 2023, 12:59PM
Why Bellicum Pharmaceuticals Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
May 8, 2023, 8:23AM
Friday, May 05, 2023
Why Atlassian Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
May 5, 2023, 12:56PM
Why Carvana Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
May 5, 2023, 8:25AM
Thursday, May 04, 2023
Galmed Pharmaceuticals Entered Into Agreement For $1.5M Equity Investment In OnKai
Benzinga Newsdesk
-
May 4, 2023, 4:32PM
Wednesday, February 08, 2023
Galmed Announces Issuance Of New Composition Of Matter Patent For Aramchol meglumine Salt
Bill Haddad
-
Feb 8, 2023, 8:11AM
Wednesday, January 04, 2023
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Jan 4, 2023, 1:17PM
Galmed Reports Results From The Open-label Part Of The ARMOR Study
Benzinga Newsdesk
-
Jan 4, 2023, 8:03AM
Show more